Discovery of a Polymorphic Biomarker More Accurately Associated with Reduced Chemotherapeutic Metabolism in a Diverse Cohort
Overview
UGT1A1 is an enzyme involved in metabolizing Irinotecan, a DNA topoisomerase class I inhibitor chemotherapeutic drug. Polymorphisms within the UGT1A1 gene promoter reduce UGT1A1 mRNA expression, rendering individuals susceptible to heightened drug toxicity. Irinotecan toxicity makes it crucial to identify the polymorphisms responsible for reduced mRNA expression and then use the polymorphism as a biomarker for personalized therapy. Previous research studied only Caucasian individuals and determined that a p olymorphism within the UGT1A1 gene promoter's TATA box was responsible for reduced mRNA expression. Although this polymorphism has been used to guide Irinotecan prescriptions, it is loosely associated with reduced mRNA expression in other populations. Comp aring mortality rates between Caucasians and African Americans prescribed Irinotecan based on the presence of the TATA box polymorphism, reveals higher mortality rates among African Americans. Therefore, this research expands its scope to encompass both Af rican-American and Caucasian populations. This study investigates a nearby single nucleotide polymorphism (SNP), rs887829, located within 300 base pairs of and in linkage disequilibrium with the TATA box. Liver samples were collected from both groups, with subsequent extraction of gDNA and total RNA. The UGT1A1 gene promoter region was amplified, and fragment analysis was conducted to genotype UGT1A1 gene promoter TATA repeats. The rs887829 polymorphism was genotyped using Illumina SNP Array, and UGT1A1 mRN A expression was quantified using real-time PCR. A linear regression model was used, which determined that the rs887829 SNP is a more accurate biomarker for reduced UGT1A1 mRNA expression, which better serves all ethnic groups.
Competition history
- JSHS 2024
Resources
Related projects
ISEF · 2024
Discovery of Rs887829 as the Genetic Polymorphism Responsible for Reduced UGT1A1 mRNA Expression in a Diverse Cohort
CSEF · 2009
Rescuing a Failed Acute Myeloid Leukemia Drug (Troxatyl) using Biomarkers
ISEF · 2025
Automated Identification of Novel Dehydrogenase Mutations Linked to Chemotherapy Sensitivity by Integrating Computational Mutation Predictions
CSEF · 2004
SNP Detection of a 410bp Region of MTRR Promoter in Colorectal Adenoma Patients
ISEF · 2015
A Novel Algorithm to Determine the Functionality of Brain Stem Glioma Associated Single Nucleotide Polymorphisms
CSEF · 2006
The Insulin-like Growth Factor Pathway and Breast Cancer Risk in African-American Women
ISEF · 2022
Prediction of Genetic Predisposition to Isoniazid-Induced Hepatic Steatosis via Computational Analysis of Genetic Biomarkers
ISEF · 2023
Platinum Induced Gene Expression Yields Insights to Chemotherapy Resistance
Closest projects by meaning, across every fair and year in the corpus.